Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (3455)	10/24/2003 11:36:48 PM
From: Brander	Read Replies (1) \| Respond to of 23958

There is also the cost issue. DSCO's product might cost significantly more to make than Curosef. I haven't down a lot of research into this, but from what I know about how DSCO's product is being made, my guess is that it is going to be very expensive. The benefits of DSCO's product might be on the benefit side of the cost/benefit equation, but, in today's world, the cost of a drug is important to consider. Another thing to consider, of course, is that if Phase III results are not what they hope for, the pps will crash.